2. Search Result
Search Result
Results for "

plaque inhibition

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0996
    Hexetidine

    NSC-17764

    		 Bacterial Fungal Infection Inflammation/Immunology
    Hexetidine (NSC-17764) is an orally active antibacterial and antifungal agent with broad antibacterial and antifungal activity. Hexetidine combined with IPBC potentiates strong fungal growth inhibition properties. Hexetidine at concentrations greater than 0.1% can cause oral ulceration. Additionally, Hexetidine improves its plaque inhibiting activities combined with zinc and has been confirmed the effectiveness on purulent wound along with ultrasound. Hexetidine is a promising candidate for research in fungus-related diseases and soft tissue purulent-inflammatory
    Hexetidine
  • HY-B1735
    Picotamide

    		Prostaglandin Receptor Cardiovascular Disease
    Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
    Picotamide
  • HY-107637
    ONO-4817

    		MMP Cardiovascular Disease
    ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .
    ONO-4817
  • HY-169047
    PAMAM dendrimer G1.5 carboxylate sodium

    PAMAM G1.5 carboxylate sodium

    		 SARS-CoV Infection
    PAMAM dendrimer G1.5 carboxylate (PAMAM G1.5 carboxylate) sodium is a polyanionic dendrimers comprising the terminal groups sodium carboxylate. PAMAM dendrimer G1.5 carboxylate shows antiviral activity with the MERS‐CoV plaque inhibition assay, with the inhibition rate of 40.5% .
    PAMAM dendrimer G1.5 carboxylate sodium
  • HY-117287A
    Deucravacitinib hydrochloride

    BMS-986165 hydrochloride

    		 Interleukin Related JAK IFNAR Inflammation/Immunology
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition .
    Deucravacitinib hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: